GluN2B Modulator Effects on Cognitive and Behavioral Tests in Transgenic Mice

Encompassing experimental results from a neuropharmacology study investigating a GluN2B-selective positive allosteric modulator. The research measures the compound's effects on synaptic plasticity in rats and its ability to reverse behavioral abnormalities in Mecp2 and Disc1 transgenic mice across multiple cognitive and behavioral tests. The specific number of data rows, columns, and sample size is not provided in the input.

Use Cases

• Analyze the relationship between systemic application of compound 175 and performance restoration in the open-field exploration test for Mecp2 overexpression mice.
• Model the impact of treatment with compound 175 on behavioral reversal in the three-chamber test for Disc1 mutant mice.
• Investigate the correlation between compound 175 application and the reversal of abnormalities in the Y-maze spontaneous alternation test.
• Examine the pharmacological properties of the lead compound 175 in facilitating hippocampal long-term depression in rats.

Strengths

• Data is derived from controlled experiments on multiple transgenic mouse models (Mecp2 and Disc1) and rats.
• Study includes results from several standardized behavioral tests (open-field, three-chamber, Y-maze, pre-pulse inhibition).
• Research focuses on a specific, novel pharmacological target (GluN2B-selective positive allosteric modulators).

Limitations

• The dataset size, structure (e.g., number of rows and columns), and specific file formats are unknown.
• Data is limited to specific animal models (Mecp2 and Disc1 transgenic mice, rats), which may not generalize to other models or humans.
• The input provides no information on data granularity, such as individual animal records, trial-level data, or raw measurements.

Provenance

Source

Borealis Harvested Dataverse

Collection Method

Experimental data from a neuropharmacology study involving animal models.

Freshness

Last updated on 2026-02-07.